Barclays
XGN icon

Barclays’s Exagen XGN Stock Holding History

Barclays’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.7K Sell
21,227
-2,374
-10% -$9.18K ﹤0.01% 4223
2025
Q4 		$143K Buy
23,601
+15,965
+209% +$145K ﹤0.01% 4468
2025
Q3 		$83.9K Buy
7,636
+2,491
+48% +$22.1K ﹤0.01% 4659
2025
Q2 		$35.9K Hold
5,145
– – ﹤0.01% 4756
2025
Q1 		$18.5K Hold
5,145
– – ﹤0.01% 4799
2024
Q4 		$21.1K Hold
5,145
– – ﹤0.01% 4917
2024
Q3 		$15.9K Hold
5,145
– – ﹤0.01% 4925
2024
Q2 		$9.36K Hold
5,145
– – ﹤0.01% 4524
2024
Q1 		$8.18K Hold
5,145
– – ﹤0.01% 4824
2023
Q4 		$10.2K Hold
5,145
– – ﹤0.01% 4968
2023
Q3 		$12.5K Hold
5,145
– – ﹤0.01% 4269
2023
Q2 		$14.9K Hold
5,145
– – ﹤0.01% 4176
2023
Q1 		$12.5K Hold
5,145
– – ﹤0.01% 4719
2022
Q4 		$12.3K Sell
5,145
-71
-1% -$182 ﹤0.01% 4887
2022
Q3 		$14K Hold
5,216
– – ﹤0.01% 4191
2022
Q2 		$30K Sell
5,216
-1,850
-26% -$10.8K ﹤0.01% 4247
2022
Q1 		$56K Buy
+7,066
New +$60.9K ﹤0.01% 4071

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Barclays's XGN Position: Q1 2026 in Review

Barclays reduced its Exagen (XGN) stake by 10% in Q1 2026, selling an estimated $9.18K and leaving 21,227 shares worth $63.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4223.

Barclays first reported a position in XGN in Q1 2022 and has held it in 17 quarters since. The position peaked at $143K in Q4 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Barclays held 21,227 shares of Exagen worth $63.7K as of Q1 2026.
  • Barclays sold 2,374 Exagen shares in Q1 2026, an estimated $9.18K.
  • Exagen made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4223 holding.
  • Barclays first reported a position in Exagen in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Exagen position peaked at $143K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.